AlzeCure Pharma

Alzheimer’s is the most common form of dementia, accounting for 60–70% of all cases, and is a fatal condition.

AlzeCure’s disease-modifying drug platform Alzstatin consists of gamma-secretase modulators (GSM), which reduce production of toxic amyloid-beta (Aβ).

The number of patients with neuropsychiatric disorders is growing globally, with 615 million people, or nearly 10% of the world’s population, currently affected.

In Alzheimer’s disease, nerve cells stop functioning properly, impairing memory and learning. AlzeCure has identified drug-like substances to address this.

AlzeCure Pharma’s stock has been listed on Nasdaq First North Premier Growth Market since November 28, 2018.

AlzeCure Pharma is a Swedish pharmaceutical company focused on researching and developing innovative treatments for Alzheimer’s disease and related disorders.

The company’s statutory auditor is appointed by the annual general meeting to review the company’s annual report, accounting, and the board’s and executive management’s work.

AlzeCure Pharma AB was founded by five researchers: Johan Sandin, Gunnar Nordvall, Pontus Forsell, Johan Lundkvist, and Magnus Halldin, all of whom had previously worked together.

AlzeCure is a Swedish pharmaceutical company developing innovative treatments for severe diseases and conditions affecting the central nervous system.

In the second quarter of 2026, AlzeCure signed two major collaboration and licensing agreements in a short period.

In 2012, the AlzeCure Foundation was established in collaboration between former AstraZeneca researchers, the Alzheimer’s Association, and Professor Bengt Winblad.